Safety and efficacy of switching to tenofovir alafenamide (TAF) in virally suppressed chronic hepatitis B (CHB) patients with hepatic impairment: week 48 results from a phase 2 open label study

2020 ◽  
Vol 73 ◽  
pp. S872
Author(s):  
Young-Suk Lim ◽  
Chun-yen Lin ◽  
Jeong Heo ◽  
Ho Bae ◽  
Wan-Long Chuang ◽  
...  
Sign in / Sign up

Export Citation Format

Share Document